Recent developments highlight the strategic acquisition of dual-targeting CAR-T assets, narrowing Q2 loss, and advancement of the in vivo CAR-T pipeline with TPST-4003.

• In February 2026, Tempest completed the acquisition of dual-targeting CAR-T assets, expanding its cell therapy portfolio with autologous, allogeneic, and in vivo CAR-T candidates [N3][S1].
• The company reported a narrowing of its Q2 loss and progress in advancing the in vivo CAR-T pipeline with TPST-4003 [N1].
• In January 2026, Tempest announced the record date for anticipated dividend distribution of warrants to stockholders [N4].
• In June 2025, Tempest received NMPA approval for a pivotal trial of amezalpat in hepatocellular carcinoma treatment in China [N5].
• In June 2025, the company announced a $4.6 million registered direct offering with an institutional investor [N6].
• The European Medicines Agency granted orphan drug designation to amezalpat in June 2025 [N7].
• The company reported a loss of $10.86 million in Q1 2025 [N8].

The company’s dual-targeting CAR-T therapies, particularly TPST-2003, have demonstrated promising early clinical efficacy and a manageable safety profile in heavily pretreated multiple myeloma patients, suggesting potential to address limitations of current CAR-T therapies. Amezalpat’s positive Phase 2 data, regulatory designations, and Phase 3 readiness position it as a potential first-in-class treatment for hepatocellular carcinoma. The externally funded Phase 2 study of TPST-1495 in familial adenomatous polyposis enables clinical advancement with limited internal capital deployment. The strategic acquisition of CAR-T assets expands the pipeline and platform capabilities. The capital-efficient development strategy leveraging partnerships and external funding may extend operational runway and support parallel program advancement [N1][N3][S1].

The company faces substantial financial challenges, including limited cash resources and ongoing net losses, raising substantial doubt about its ability to continue as a going concern without additional financing. Access to committed funding under the Factor Credit Line is uncertain, and failure to secure sufficient capital may force delays or termination of development programs. The company has received Nasdaq notices for non-compliance with listing requirements, which could lead to delisting and reduced market liquidity. Clinical programs remain in early stages with limited patient data, and the durability and reproducibility of clinical benefits are not yet established. Management and board turnover may disrupt strategic execution and governance. The competitive oncology landscape and regulatory hurdles present additional risks to successful product development and commercialization [S2].

Tempest Therapeutics’ moat is based on its diversified pipeline of next-generation dual-targeting CAR-T therapies and small molecule candidates addressing significant unmet medical needs in oncology. The dual-targeting CAR-T approach aims to mitigate tumor antigen escape and improve durability of response, which are limitations of existing single-target CAR-T therapies. The company’s portfolio includes autologous, allogeneic, and in vivo CAR-T modalities, potentially broadening applicability and scalability. Regulatory designations such as orphan drug and fast track status for key candidates like amezalpat provide potential regulatory and market advantages. Strategic partnerships and licensing agreements, including the acquisition of CAR-T assets and collaboration with Novatim and Factor Bioscience, support development and capital efficiency. However, the company remains in early clinical stages with limited commercial products, and its competitive position depends on successful clinical development and regulatory approvals.

• Financial Sustainability: The company has limited cash and cash equivalents ($0.779 million as of June 30, 2026) and a current ratio below 1, with substantial doubt about its ability to continue as a going concern without additional financing [S2].
• Nasdaq Listing Compliance: The company has received notices for non-compliance with minimum stockholders’ equity and board independence requirements, risking potential delisting and adverse effects on stock liquidity and trading [S2].
• Clinical Development Risks: Clinical programs are in early phases with limited patient data; efficacy and safety profiles require further validation to confirm clinical benefit and regulatory approval potential [S1].
• Management and Governance Instability: Recent significant turnover in senior management and board members may disrupt strategic execution, internal controls, and investor confidence [S2].
• Capital Access Uncertainty: Access to committed funding under the Factor Credit Line is uncertain, and failure to secure additional capital may limit operational capabilities and development progress [S2].

• Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates [S1].
• In February 2026, Tempest acquired rights to a portfolio of dual-targeting CAR-T product candidates, including TPST-2003, an autologous CD19/BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma (rrMM) [S1].
• The company’s pipeline includes autologous, allogeneic, and in vivo dual-targeting CAR-T therapies: TPST-2003, TPST-2206, TPST-3003, TPST-3206, and TPST-4003 [S1].
• Tempest’s small molecule candidates include amezalpat (TPST-1120), which completed Phase 2 in first-line hepatocellular carcinoma (HCC) and is Phase 3-ready, and TPST-1495, planned for Phase 2 study in familial adenomatous polyposis (FAP) with NCI funding [S1].
• Amezalpat showed a six-month improvement in median overall survival in a Phase 1b/2 study combined with atezolizumab and bevacizumab versus standard of care in unresectable/metastatic HCC [S1].
• Amezalpat received FDA Orphan Drug Designation and Fast Track Designation, and EMA Orphan Drug Designation for HCC [S1].
• TPST-1495 is a dual antagonist of EP2 and EP4 receptors of prostaglandin E2, implicated in multiple cancers, with a Phase 2 trial authorized by FDA and funded by NCI [S1].
• TPST-2003 clinical data from Phase 1/2 IIT and REDEEM-1 Phase 1/2a trials in rrMM showed 100% overall response rate among 25 evaluable patients and 100% complete response rate in 6 evaluable patients in REDEEM-1 [S1].
• Safety profile of TPST-2003 includes no Grade 3 or higher cytokine release syndrome and low-grade neurotoxicity in one patient [S1].
• The company pursues a capital-efficient development strategy including partner support and external funding to extend operational runway [S1].
• Financial snapshot as of June 30, 2026: cash and equivalents $0.779 million, current assets $1.697 million, current liabilities $4.45 million, net loss $5.244 million for Q2 2026, EPS basic and diluted -$0.34 [S2].
• Liquidity ratios as of June 30, 2026: current ratio 0.38, cash ratio 3.42 [S2].
• There is substantial doubt about the company’s ability to continue as a going concern due to limited cash resources and need for additional financing [S2].
• The company has a financing commitment (FCL) with Factor Bioscience up to $20 million, with $11.8 million available as of the latest report, but access to funds is uncertain [S2].
• The company’s common stock is listed on Nasdaq but has received notices for non-compliance with minimum stockholders’ equity and board independence requirements, with ongoing efforts to regain compliance [S2].
• Recent developments include closing the strategic acquisition of dual-targeting CAR-T assets in February 2026 [N3].
• Recent news highlights narrowing Q2 loss and advancement of in vivo CAR-T pipeline with TPST-4003 [N1].
• The company announced a record date for anticipated dividend distribution of warrants to stockholders in January 2026 [N4].
• Received NMPA approval for pivotal trial of amezalpat in hepatocellular carcinoma treatment in China as of June 2025 [N5].
• Announced $4.6 million registered direct offering with institutional investor in June 2025 [N6].
• EMA granted orphan drug designation to amezalpat in June 2025 [N7].
• Reported a loss of $10.86 million in Q1 2025 [N8].